Cyclin A as a Predictive Factor for Chemotherapy Response in Advanced Head and Neck Cancer

Rodríguez-Pinilla, María; Rodríguez-Peralto, José L.; Hitt, Ricardo; Sánchez, José Javier; Ballestı́n, Claudio; Díez, Ana; Sánchez-Verde, Lydia; Alameda, Francesc; Sanchez-Cespedes, Montse

doi:10.1158/1078-0432.ccr-04-0771

Cited by 28 publications

(42 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The statistical analysis and criteria for quantification has been previously described (67). Briefly, the frequencies were compared either by the Fisher's exact test or the m 2 contingency test using the SPSS program version 10.0.5 (SPSS, Inc., Chicago, IL), and differences with a P < 0.05 were considered as statistically significant.…”

Section: Discussionmentioning

confidence: 99%

“…*, P < 0.05; **, P < 0.01; ***, P < 0.001. patients was 56 years; the median overall survival for the cohort was 37.7 months; the median to progression was 29.1 months. The characteristics of these cases have already been reported (67). Tumor biopsies were taken at diagnosis before initiation of treatment.…”

Section: Samplesmentioning

confidence: 99%

“…Biopsies were fixed in formalin and embedded in paraffin. These biopsies were used to prepare a tissue array made with a tissue arrayer (Beecher Instruments, Silver Spring, MD) as previously reported (67). The biopsies were examined by two pathologists who selected tumor areas, avoiding those with necrosis, inflammation, and keratinization.…”

Section: Samplesmentioning

confidence: 99%

“…The p53 was detected with clone DO-7 (Novocastra, Newcastle upon Tyne, United Kingdom); cdc2 with antibody 1 (Transduction Laboratory, Lexington, KY); CDK6 with antibody BD (BD PharMingen, San Diego, CA); cyclin A with antibody GEG (Novocastra); hdm2 with clone 1F2 (Oncogene, La Jolla, CA); and Ki67 with clone M1B1 (DAKO, Glostrup, Denmark). The processing of the biopsies, the dilutions used for primary antibodies, and the secondary antibodies for detection have all been described (67). The cutoff criteria has been previously reported (67).…”

Section: Antibodiesmentioning

confidence: 99%

“…The processing of the biopsies, the dilutions used for primary antibodies, and the secondary antibodies for detection have all been described (67). The cutoff criteria has been previously reported (67). Briefly, hdm2 immunostaining was scored as negative when <5% of tumor cells presented immunoreactivity.…”

Section: Antibodiesmentioning

confidence: 99%

See 4 more Smart Citations

VRK1 Signaling Pathway in the Context of the Proliferation Phenotype in Head and Neck Squamous Cell Carcinoma

Santos

Rodríguez-Pinilla²,

Vega

et al. 2006

Molecular Cancer Research

105

View full text Add to dashboard Cite

The vaccinia-related kinase (VRK) proteins are a new family with three members in the human kinome. The VRK1 protein phosphorylates several transcription factors and has been postulated to be involved in regulation of cell proliferation. In normal squamous epithelium, VRK1 is expressed in the proliferation area. Because VRK1 can stabilize p53, the expression of the VRK1 protein was analyzed in the context of the p53 pathway and the proliferation phenotype in a series of 73 head and neck squamous cell carcinomas. VRK1 protein level positively correlated with p53 response proteins, particularly hdm2 and p21. The VRK1 protein also correlated positively with several proteins associated with proliferation, such as cyclin-dependent kinase 2 (CDK2), CDK6, cdc2, cyclins B1 and A, topoisomerase II, survivin, and Ki67. The level of VRK1 protein behaves like a proliferation marker in this series of head and neck squamous cell carcinomas. To identify a possible regulatory role for VRK1 and because it regulates gene transcription, the promoters of two genes were studied, CDK2 and SURVIVIN, whose proteins correlated positively with VRK1. VRK1 increases the activity of both the CDK2 and SURVIVIN gene promoters. The expression of VRK1 was analyzed in the context of regulators of the G 1 -S transition. VRK1 protein levels increase in response to E2F1 and are reduced by retinoblastoma and p16. These data suggest that VRK1 might play a role in cell cycle regulation and is likely to represent the beginning of a new control mechanism of cell cycle, particularly late in the G 1 -S phase.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Samplesmentioning

confidence: 99%

Section: Samplesmentioning

confidence: 99%

Section: Antibodiesmentioning

confidence: 99%

Section: Antibodiesmentioning

confidence: 99%

See 3 more Smart Citations

VRK1 Signaling Pathway in the Context of the Proliferation Phenotype in Head and Neck Squamous Cell Carcinoma

Santos

Rodríguez-Pinilla²,

Vega

et al. 2006

Molecular Cancer Research

105

View full text Add to dashboard Cite

show abstract

Utility of the GeneSearch breast lymph node assay for the rapid evaluation of sentinel lymph nodes in breast cancer

Funasako

Uenosono

Hirata

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The potential for reducing the need for second surgery for axillary lymph node dissection (ALND) has made the intraoperative evaluation of sentinel lymph nodes (SLNs) attractive. The goal of the current study was to evaluate the clinical application of the breast lymph node (BLN) assay, a real-time reverse transcriptase-polymerase chain reaction assay for SLN metastases, by comparing this test with routine pathologic examination. METHODS: A total of 117 patients with breast cancer underwent breast surgery with SLN biopsy. Each SLN was cut in half along the plane of the longest dimension. Half of each lymph node was examined by the 2 markers of the BLN assay, mammaglobin and cytokeratin 19, and the other half was examined by hematoxylin and eosin staining (H&E) and immunohistochemical staining (IHC) for pancytokeratins. RESULTS: A total of 204 SLNs were obtained from 117 patients. H&E staining identified metastases in 31 SLNs (15.2%), and IHC staining detected metastases in 6 SLNs; 40 SLNs from 32 patients were found to be positive for metastasis using the BLN assay. The assay results were correlated with the pathologic diagnoses by H&E and IHC staining (P <.001). The sensitivity of the BLN assay compared with pathologic findings classified according to the TNM classification was 95.7% for macrometastases, 60.0% for micrometastases, and 55.6% for isolated tumor cells. CONCLUSIONS: The 2-marker BLN assay performs in a manner that is comparable to, and analyzes more tissue than, routine pathologic examination. Therefore, clinical intraoperative use of the BLN assay for SLNs may result in a reduction in the need for second surgery for ALND. Cancer 2010;116:4450-5.

show abstract

Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression

Rittá¹,

Andrea

Mondini

et al. 2009

Head & Neck

View full text Add to dashboard Cite

show abstract

Cyclin A as a Predictive Factor for Chemotherapy Response in Advanced Head and Neck Cancer

Abstract: Conclusions: Our results provide detailed information on the molecular profile of cell cycle components in HNSCCs and identify CA-negative-expressing tumors as an independent marker of tumor progression and poor response to chemotherapy in patients diagnosed with advanced HNSCC.

Cited by 28 publications

References 25 publications

VRK1 Signaling Pathway in the Context of the Proliferation Phenotype in Head and Neck Squamous Cell Carcinoma

VRK1 Signaling Pathway in the Context of the Proliferation Phenotype in Head and Neck Squamous Cell Carcinoma

Utility of the GeneSearch breast lymph node assay for the rapid evaluation of sentinel lymph nodes in breast cancer

Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression

Contact Info

Product

Resources

About